Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared
On the surface, Vertex Pharmaceuticals' (NASDAQ: VRTX) fourth-quarter earnings didn't look particularly good. But there's more to the story as Fool.com contributors Brian Orelli and Keith Speights note in this video from Motley Fool Live, recorded on Feb. 8. The duo also discuss the difference between the launch of Tikafta in the U.S. and the rollout of the drug in Europe, where it goes by the name Kaftrio.
Source Fool.com
